SecBot SecBot

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0002023311 Biotech & Drug Discovery
$15.44 +0.52 (+3.49%)
Oct 23 4:00 PM ET · prev $14.92
Market cap
$1.4B
Small cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
🔒 Subscribers only
1 year
−56.5%
from $35.46 · Oct 24
30 days
+1.4%
from $15.23
52-week range
$14.55–35.46
−56% from high · low Oct 8
Avg volume 20D
7.7K
shares / day
Short interest
9.3K
≈0.0% of shares · −53.4%
Days to cover
1.5
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 2 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 7/7
Strongest BULLISH Ascentage Pharma announced that its Bcl-2 inhibitor lisaftoclax (APG-2575) received Breakthrough Therapy…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better.

  • Short sellersCOVERING

    Short interest −53.4% to 9.3K shares. 1.5 days to cover, ≈0.0% of shares.

  • TrendDOWNTREND

    5% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYADD919$16.1K
UBS Group AGNEAR_EXIT15$263.00
MORGAN STANLEYDOUBLED498$11.9K
UBS Group AGNEAR_EXIT124$3.0K
UBS Group AGNEAR_EXIT4,232$111.0K
Pacer Advisors, Inc.ADD1,663$39.1K
UBS Group AGDOUBLED18,345$716.2K
NEOS Investment Management LLCTRIM10,385$412.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy4Buy5Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 16, 2026William Blair
INITIATE
INITIATEOutperform
Oct 14, 2026Citigroup
INITIATE
INITIATEBuy
Oct 13, 2026Citizens
INITIATE
INITIATEMarket Outperform
Oct 8, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 21, 2026BTIG
REITERATE
REITERATEBuy
Jun 15, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
May 21, 2026
Yang Dajun
Chairman and CEO
EXERCISE95,575 sh
May 21, 2026
Zhai Yifan
Chief Medical Officer
EXERCISE92,746 sh
May 21, 2026
Zhai Yifan
Chief Medical Officer
EXERCISE95,575 sh
May 21, 2026
Yang Dajun
Chairman and CEO
EXERCISE92,746 sh
May 20, 2026
Yang Dajun
Chairman and CEO
AWARD95,575 sh
May 20, 2026
Yang Dajun
Chairman and CEO
AWARD298,194 sh
May 20, 2026
Zhai Yifan
Chief Medical Officer
AWARD214,988 sh
May 20, 2026
Zhai Yifan
Chief Medical Officer
AWARD103,365 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
9,250
shares short
-53.4%
vs prior settlement
1.5
days to cover
≈0.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Ascentage Pharma disclosed that its trustee purchased 200,000 existing shares on-market for ~HK$5.74 million (avg…
6-K — Impact 2/10
Oct 21, 2026 SEC
Ascentage Pharma announced that its Bcl-2 inhibitor lisaftoclax (APG-2575) received Breakthrough Therapy Designation…
6-K — Impact 6/10
Oct 20, 2026 Other
Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
Lisa granted breakthrough designation for Lisa in China...
Oct 15, 2026 SEC
Ascentage Pharma's trustee purchased 200,000 existing shares (0.05% of issued shares) on-market for HK$5.78 million…
6-K — Impact 1/10
Jul 26, 2026 Press
Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, was ranked No. 3 in The Medicine Maker Power List 2026 Small…
Impact 1/10
Jun 30, 2026 Inst.
MORGAN STANLEY — ADD
919 shares ($16.1K)
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
15 shares ($263.00)
Jun 14, 2026 Press
Ascentage Pharma presented 17 clinical updates at EHA2026, including eight posters, for olverembatinib…
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 20, 2026
Press release
Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
Lisa granted breakthrough designation for Lisa in China...
Sep 2, 2026
Press release
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the…
Aug 19, 2026
Earnings
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Earnings release
Aug 5, 2026
Press release
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
In a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), please note that in…
Aug 2, 2026
Press release
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
They appointed a New CCO and CBO to highlight their commitment to US commercialization

SecBot reports

20 filings · 8 press releases · 3 bullish · 2 bearish · 15 neutral
All AAPG filing & press-release reports (29)